C-o- Group In R Patents (Class 514/622)
-
Publication number: 20140171468Abstract: The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.Type: ApplicationFiled: October 1, 2013Publication date: June 19, 2014Applicant: GTX, INC.Inventors: James T. Dalton, Mitchell S. Steiner, Jeetendra Eswaraka
-
Publication number: 20140171490Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.Type: ApplicationFiled: August 9, 2013Publication date: June 19, 2014Applicant: PHARMALINGT INC.Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
-
Publication number: 20140155488Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent the presence or absence of a double bond which can be in the cis or trans configuration and A, B, Z, X, R1 and R2 are as defined in the specification and a penetration enhancer. Such compositions are used in stimulating hair growth of human or non-human animals.Type: ApplicationFiled: February 7, 2014Publication date: June 5, 2014Applicant: ALLERGAN, INC.Inventors: KEVIN S. WARNER, KRISTIN B. PRINN, CHETAN P. PUJARA, PRAMOD SARPOTDAR, JOHN T. TROGDEN, ADNAN K. SALAMEH
-
Publication number: 20140142137Abstract: Provided herein, inter alia, are novel compounds for the inhibition of HIV integrase. The compounds disclosed herein are useful for methods of treating HIV infection in a subject in need thereof.Type: ApplicationFiled: August 2, 2013Publication date: May 22, 2014Applicants: National Institutes of Health, The Regents of the University of CaliforniaInventors: Seth M. Cohen, Arpita Agrawal, Jamie DeSoto, Yves Pommier, Kasthuraiah Maddali
-
Publication number: 20140142134Abstract: Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such as Salmonella spp., Shigella flexneri, Psendomonas spp., Yersinia spp., en tero pathogenic and enteroinvasive Escherichia coli, and Chlamydia spp. having such type III secretion systems.Type: ApplicationFiled: July 13, 2012Publication date: May 22, 2014Applicant: MICROBIOTIX, INC.Inventors: Donald T. Moir, Daniel Aiello, Norton P. Peet, John D. Williams, Matthew Torhan
-
Publication number: 20140128329Abstract: Compositions and methods related to ophthalmic use of polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers and therapeutic uses are described herein.Type: ApplicationFiled: January 10, 2014Publication date: May 8, 2014Applicant: Allergan, Inc.Inventors: Anuradha V. Gore, Chetan P. Pujara, Richard S. Graham, Melissa Gulmezian, Kristin Prinn, Ramakrishnan Srikumar
-
Publication number: 20140113974Abstract: The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.Type: ApplicationFiled: December 20, 2013Publication date: April 24, 2014Applicant: Allergan, Inc.Inventors: Gyorgy F. Ambrus, Kiomars Karami, Ke Wu
-
Patent number: 8703823Abstract: Compositions, methods and kits are provided for the treatment of migraines. The compositions, methods and kits include an effective dose of trimethobenzamide and an ethanolamine antihistamine that, when administered to an individual suffering from migraine headaches, will alleviate symptoms associated with the migraine headaches. Compositions, methods, and kits for the treatment of migraines include pharmaceutical compositions of trimethobenzamide and diphenhydramine.Type: GrantFiled: September 16, 2008Date of Patent: April 22, 2014Inventor: Foad Salehani
-
Publication number: 20140107194Abstract: Compounds particularly for use in an autoimmune inflammatory disease and especially the treatment of inflammatory bowel disease have the formula: wherein R is selected from one or more of the same or different of hydrogen, hydroxyl, optionally substituted alkyl, optionally substituted aryl, alkoxy, aryloxy, thiol, and optionally substituted amino, and wherein R1 is selected from one or more of the same or different of hydrogen, acetyl, optionally substituted alkyl, optionally substituted aryl, and an amino acid selected from leucine, valine, isoleucine, and glycine.Type: ApplicationFiled: July 20, 2012Publication date: April 17, 2014Applicant: Venantius LimitedInventors: Neil Frankish, Helen Sheridan
-
Publication number: 20140107050Abstract: The present invention is directed to a composition including N-Coumaroyldopamine and a catechol-o-methyltransferase (COMT) inhibitor for promoting weight loss in a user.Type: ApplicationFiled: October 14, 2013Publication date: April 17, 2014Applicant: Redefine Nutrition, LLCInventors: Kyung S. Kim, Bryan J. Krause
-
Publication number: 20140100287Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: December 9, 2013Publication date: April 10, 2014Applicant: Allergan, Inc.Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
-
Patent number: 8686048Abstract: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.Type: GrantFiled: May 5, 2011Date of Patent: April 1, 2014Assignee: Rhizen Pharmaceuticals SAInventors: Meyyappan Muthuppalaniappan, Prashant K. Bhavar, Srikant Viswanadha, Swaroop Kumar V. S. Vakkalanka, Gayatri S. Merikapudi
-
Publication number: 20140088107Abstract: The present invention relates to an aqueous ophthalmic preparation comprising a PGF2? analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension.Type: ApplicationFiled: November 25, 2013Publication date: March 27, 2014Applicant: RATIOPHARM GMBHInventors: Dieter Swatscheck, Max-Werner Scheiwe, Michael Florenski
-
Patent number: 8673953Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.Type: GrantFiled: January 6, 2012Date of Patent: March 18, 2014Assignee: Allergan, Inc.Inventors: Stuart D. Shanler, Andrew Ondo
-
Publication number: 20140066466Abstract: Described herein are compositions that inhibit the production of TNF? downstream of CD40 activation. As such, also described are various methods of using compositions exhibiting this activity for the treatment or prevention of inflammatory diseases associated with TNF? production or CD40 activation.Type: ApplicationFiled: March 12, 2012Publication date: March 6, 2014Applicant: President and Fellows of Harvard CollegeInventor: Junying Yuan
-
Patent number: 8664275Abstract: The crystalline form A of Bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2? are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, 20.8±02° and 22.8±0.2° in the X-ray powder diffraction pattern of the crystalline form A.Type: GrantFiled: July 30, 2010Date of Patent: March 4, 2014Assignee: Shanghai Techwell Biopharmaceutical Co., Ltd.Inventors: Bingming He, Zhijun Tang, Zhonghao Zhuo, Yunman Zheng, Xiaoliang Gao, Xiaoming Ji
-
Publication number: 20140057946Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.Type: ApplicationFiled: February 13, 2013Publication date: February 27, 2014Applicant: GtxInventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss
-
Publication number: 20140057953Abstract: The invention relates to selective, non-steroidal 17beta-hydroxysteroid dehydrogenase type 2 (l7beta-HSD2) inhibitors of formula (I), their production and use, notably for the treatment and prophylaxis of sex steroid deficient diseases like osteoporosis in men and women.Type: ApplicationFiled: March 2, 2012Publication date: February 27, 2014Inventors: Rolf Hartmann, Sandrine Marchais-Oberwinkler, Kuiying Xu, Ruth Werth
-
Publication number: 20140057985Abstract: The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC), metastatic castration resistant prostate cancer (mCRPC) and palliative treatment of prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC), and methods of reducing high or increasing PSA levels and/or increasing SHBG levels in a subject suffering from prostate cancer, advanced prostate cancer, castration resistant prostate cancer (CRPC) and metastatic castration resistant prostate cancer (mCRPC). The compounds of this invention suppress free or total testosterone levels despite castrate levels secondary to ADT and reduce high or increasing PSA levels.Type: ApplicationFiled: December 13, 2012Publication date: February 27, 2014Applicant: GtxInventors: James T. Dalton, Mitchell S. Steiner, Christopher C. Coss
-
Publication number: 20140045945Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.Type: ApplicationFiled: September 19, 2013Publication date: February 13, 2014Applicant: Allergan, Inc.Inventors: Michael R. Robinson, James A. Burke, Rhett M. Schiffman, Alazar N. Ghebremeskel
-
Publication number: 20140039060Abstract: The invention relates to compounds and their use in treating cell proliferative disorders, more specifically Syk tyrosine kinase-mediated disorders.Type: ApplicationFiled: October 9, 2013Publication date: February 6, 2014Inventor: Eliahu Kaplan
-
Publication number: 20140030301Abstract: The present invention relates to an aqueous pesticidal composition having excellent pesticidal activity, particularly a pesticidal composition comprising a pesticidal active ingredient, a carboxy-modified methyl methacrylate-butadiene copolymer, a surfactant and water, wherein the amount of the carboxy-modified methyl methacrylate-butadiene copolymer is 20-100 parts by weight relative to 100 parts by weight of the pesticidal active ingredient and the amount of the surfactant is 0.1-50 parts by weight relative to 100 parts by weight of the pesticidal active ingredient.Type: ApplicationFiled: March 7, 2012Publication date: January 30, 2014Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: Motofumi Mizutani, Yumiko Kozuki, Maki Owaki, Masanao Takaishi, Masato Soma
-
Patent number: 8629185Abstract: The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystalline form II is readily prepared from crystalline form I.Type: GrantFiled: November 22, 2010Date of Patent: January 14, 2014Assignee: Allergan, Inc.Inventors: Gyorgy F. Ambrus, Kiomars Karami, Ke Wu
-
Publication number: 20140005240Abstract: This invention relates to the use of bis- and tris-dihydroxyaryl compounds as well as sulfonamides, heteroaryls, tricycloalkyl and their analogs and pharmaceutically acceptable salts, for modulating tau aggregation and alleviating tauopathies, such as Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and familial frontotemporal dementia/Parkinsonism linked to chromosome 17 (FTDP-17), amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.Type: ApplicationFiled: July 18, 2013Publication date: January 2, 2014Inventors: Alan D. Snow, Qubai Hu, Thomas Lake, Judy Cam
-
Publication number: 20140005263Abstract: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.Type: ApplicationFiled: May 21, 2013Publication date: January 2, 2014Applicant: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
-
Patent number: 8614205Abstract: The present invention discloses methods of modulating the activity of Group I mGluRs using a defined class of benzamide compounds. In one embodiment, methods of modulating the activity of mGluR1 are provided. In another embodiment, methods of modulating the activity of mGluR5 are provided. In still another embodiment, methods of simultaneously modulating the activities of both mGluR1 and mGluR5 are provided. The present invention also provides methods of treating diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of benzamide compounds. The present invention further provides methods of preventing diseases or disorders which are mediated in full or in part by Group I mGluRs using one or more compounds belonging to the defined class of compounds.Type: GrantFiled: June 2, 2012Date of Patent: December 24, 2013Inventors: Richard D Wood, William Welsh
-
Publication number: 20130338092Abstract: This invention relates to high-throughput, semi-automated methods for identifying compounds that are effective in targeting leukemia stem cells, as well as compounds identified by those methods and uses thereof for treating leukemia.Type: ApplicationFiled: August 16, 2013Publication date: December 19, 2013Inventors: Kimberly Hartwell, Malcolm A.S. Moore, David T. Scadden, Stuart L. Schreiber, Todd R. Golub, Benito Munoz, Benjamin L. Ebert, Andrew M. Stern, Peter G. Miller, D. Gary Gilliland, Anne Van Dyk Carpenter, David J. Logan, Joseph Negri, Nicola Tolliday, Alykhan Shamji, Siddhartha Mukherjee, Alison Stewart
-
Patent number: 8604083Abstract: Compounds useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis, are disclosed.Type: GrantFiled: July 2, 2007Date of Patent: December 10, 2013Assignee: Wellstat Therapeutics CorporationInventors: Shalini Sharma, Reid W. Von Borstel, Kirvin L. Hodge, Michael K. Bamat, Stephen D. Wolpe
-
Publication number: 20130324555Abstract: The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein, alone or in combination with one or more other active or excipient pharmaceutical substances. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein. The present invention is further directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a combination of salicylanilides or salicylanilide derivatives, disclosed herein, further comprised of one or more active or excipient pharmaceutical substances.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Inventors: Richard Delarey Wood, Rima McLeod, Ernest Mui, Alina Fomovska, William Welsh
-
Patent number: 8592438Abstract: A plant disease control composition comprising, as an active ingredient, a compound of formula (I) or a salt thereof, and one or more anilinopyrimidine compounds selected from the group consisting of 4,6-dimethyl-N-phenyl-2-pyrimidinamine, 4-methyl-N-phenyl-6-(1-propynyl)-2-pyrimidinamine and 4-cyclopropyl-6-methyl-N-phenyl-2-pyrimidinamine has an excellent plant disease control effect.Type: GrantFiled: March 16, 2009Date of Patent: November 26, 2013Assignee: Sumitomo Chemical Intellectual Property Service, LtdInventors: Masanao Takaishi, Norio Kimura
-
Publication number: 20130310386Abstract: Methods for treating eye diseases associated with inflammation and/or vascular proliferation in subjects are disclosed. The methods include administering therapeutically effective amounts of a tranilast compound, in particular (E)-2-[[3-(3-Methoxy-4-propargyloxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or (E)-2-[[3,4-Bis(difluoromethoxy)phenyl)-1-oxo-2-propenyl]amino]benzoic acid or pharmaceutically acceptable salts or solvates thereof.Type: ApplicationFiled: November 10, 2011Publication date: November 21, 2013Applicant: Fibrotech Therapeutics Pty LtdInventors: Darren James Kelly, David Stapleton
-
Publication number: 20130309330Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).Type: ApplicationFiled: January 24, 2012Publication date: November 21, 2013Applicant: Inceptum Research & Therapeutics, Inc.Inventor: Fabrizio G. Mastronardi
-
Publication number: 20130296435Abstract: Methods and compositions for stimulating the growth of hair are disclosed wherein said compositions include a cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl compound represented by the formula I wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is preferred for this treatment.Type: ApplicationFiled: July 9, 2013Publication date: November 7, 2013Inventors: David F. Woodward, Amanda M. VanDenburgh
-
Publication number: 20130289118Abstract: The subject of the invention is a group of new derivatives of aminoalkanols, more specifically [(phenoxy)alkyl]aminoalkanols and [(phenoxy)acyl]aminoalkanols, their method of obtaining and their use for production of a medicine which is used in the prophylaxis, prevention and/or treatment of diseases or symptoms having neurological background and for production a medicine with anticonvulsant activity, which is used in seizures of various origin, also in the limbic system, in myoclonic or sound-induced seizures, in psychomotor epilepsy, as well as relieving neuropathic or inflammatory pain.Type: ApplicationFiled: March 29, 2013Publication date: October 31, 2013Applicant: Uniwersytet JagiellonskiInventors: Henryk Marona, Anna Waszkielewicz, Katarzyna Kiec-Kononowicz
-
Publication number: 20130289123Abstract: The present invention is directed to methods of modulating the activity of an isoform of manganese superoxide dismutase which is useful for the treatment of diseases such as neurodegenerative diseases and heart failure.Type: ApplicationFiled: March 28, 2013Publication date: October 31, 2013Applicant: MitoTek, LLCInventor: Paul Q. Anziano
-
Publication number: 20130281454Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.Type: ApplicationFiled: April 23, 2013Publication date: October 24, 2013Applicant: ALLERGAN, INC.Inventors: RHETT M. SCHIFFMAN, JUNE CHEN
-
Publication number: 20130281444Abstract: The present invention provides a biphenyl benzamide-derived derivatives, which structure is selected from formula I or formula II: and the synthesis and the application thereof.Type: ApplicationFiled: August 9, 2012Publication date: October 24, 2013Inventors: Deh-Ming CHANG, Hsu-Shan HUNAG, Chia-Chung LEE, Chun-Liang CHEN
-
Publication number: 20130281394Abstract: Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administering a composition comprising a chemosensory receptor ligand. Also provided herein are chemosensory receptor ligand compositions and methods for the preparation thereof for use in the methods of the present invention.Type: ApplicationFiled: October 18, 2011Publication date: October 24, 2013Applicant: ELCELYX THERAPEUTICS, INC.Inventors: Alain D. Baron, Martin R. Brown, Christopher R.G. Jones, Nigel R.A. Beeley
-
Publication number: 20130274323Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2, Pgp, or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering effective amounts of certain compounds to the mammal, for example, a compound of the formula (I): wherein R1, R2, R3, X1, X2, X3, a, and b are as described herein. Uses of these compounds in the preparation of a medicament are also disclosed. Also disclosed are compounds of formula (II), pharmaceutical compositions comprising such compounds and uses thereof.Type: ApplicationFiled: June 5, 2013Publication date: October 17, 2013Inventors: Curtis J. Henrich, Heidi R. Bokesch, Laura K. Cartner, Richard W. Fuller, Kirk R. Gustafson, Kentaro Takada, James B. McMahon, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean
-
Publication number: 20130267571Abstract: The present application provides a terpene analogue of Formula (I) or a pharmaceutically acceptable isomer, salt or ester thereof, and methods and uses thereof for treating neurological conditions such as pain in general and neuropathic pain. These terpene analogues can also be used to treat other electrical disorders in the central and peripheral nervous system. Also provided are methods of synthesizing the terpene analogues of Formula I.Type: ApplicationFiled: September 14, 2011Publication date: October 10, 2013Applicant: NeuroQuest Inc.Inventors: Mark A. Reed, Donald Weaver, Shengguo Sun, Alexander McLellan, Erhu Lu
-
Patent number: 8552065Abstract: The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused by an abnormal excess of melanin or a disease caused by melanocyte hyperplasia comprising the same as an active ingredient. The biarylamide derivative of the present invention inhibits melanin production and thus inhibits melanocyte hyperplasia. Therefore, a cosmetic composition comprising the biarylamide is excellent in a whitening effect, and a pharmaceutical composition comprising the biarylamide is effective in the prevention or treatment of pigmentation disorders of skin such as lentigo, melasma, freckle, etc. and malignant melanoma.Type: GrantFiled: July 25, 2012Date of Patent: October 8, 2013Assignee: Catholic University Industry Academy Cooperation FoundationInventor: Dong Heon Shin
-
Publication number: 20130261178Abstract: A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: wherein Z1 is C1-C4 linear or branched alkyl or alkenyl; R4 is selected from unsubstituted and substituted C3-C3 cycloalkyl, C1-C8 linear or branched alkyl, C2-5 alkenyl, C6-C10 heteroaryl or aryl, or C3-C8 heterocyclyl which may be part unsaturated, and combinations thereof; Z is linear C2-3 alkylene; X1 is selected from NH and O; X2 is selected from unsaturated C and unsaturated S; and X3 is selected from NH and CH2; or one of X1 and X3 is a single bond; or X1 is O and X2 and X3 together are a single bond; and R7 is selected from oxo, F, Cl, Br, CN, NH2, NR92, NO2, CF3, OR9, COR9, OCOR9, COOR9, NR9COR9, CONR92SO2NR92, NR9SO2R9; and R8 is selected from C1-5 alkyl, C1-5 alkoxyl, C2-5 alkenyl or alkynyl, C6-10 aryl and C3-8 cycloalkyl and combinations thereof, which may be unsubstituted or further substituted by one or more F, Cl, Br, CN, NH2, NR32, NO2, CF3;Type: ApplicationFiled: July 5, 2010Publication date: October 3, 2013Inventors: Shailesh Mistry, Etienne Daras, Christophe Fromont, Gopal Jadhav, Peter Martin Fischer, Barrie Kellam, Stephen John Hill, Jillian Glenda Baker
-
Publication number: 20130261142Abstract: The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516.Type: ApplicationFiled: December 15, 2010Publication date: October 3, 2013Inventor: Hung-Cheng Lai
-
Publication number: 20130245019Abstract: Acrylamido derivatives useful as therapeutic agents, particularly for the prevention and/or treatment of diseases and conditions associated with the activity of the mitochondrial permeability transition pore (MPTP), such as the diseases characterized by ischemia/reperfusion, oxidative or degenerative tissue damage, are herein described. These compounds belong to the structural formula (I) wherein R, R?, R?, W and a are as defined in the specification. The invention also relates to the preparation of these compounds, as well as to pharmaceutical compositions comprising them.Type: ApplicationFiled: April 30, 2013Publication date: September 19, 2013Applicant: CONGENIA SRLInventors: Daniele Fancelli, Mario Varasi, Simon Plyte, Marco Ballarini, Anna Cappa, Giacomo Carenzi, Saverio Minucci, Gilles Pain, Manuela Villa
-
Publication number: 20130245124Abstract: The present invention is directed to preservative-free solutions of bimatoprost for lowering intra-ocular pressure and treatment of glaucoma.Type: ApplicationFiled: July 28, 2011Publication date: September 19, 2013Applicant: ALLERGAN, INC.Inventors: Sukhon Likitlersuang, Ajay Parashar, Chetan P. Pujara, William F. Kelly
-
Publication number: 20130236557Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the ploymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.Type: ApplicationFiled: April 12, 2013Publication date: September 12, 2013Applicant: Allergan, Inc.Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
-
Publication number: 20130231341Abstract: Novel substituted benzamide based inhibitors, their use in therapy, pharmaceutical compositions comprising the compounds, the use of said compounds in the manufacture of medicaments, and therapeutic methods comprising the administration of said compounds are described. The present compounds modulate the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1) and are accordingly useful in the treatment of diseases in which such a modulation is beneficial, such as the metabolic syndrome.Type: ApplicationFiled: January 11, 2013Publication date: September 5, 2013Applicant: HIGH POINT PHARMACEUTICALS, LLCInventor: Soren Ebdrup
-
Patent number: 8518940Abstract: The present invention embraces compounds selected for interacting with the Fingers-Palm pocket of telomerase and use thereof for modulating the activity of telomerase and preventing or treating diseases or conditions associated with telomerase.Type: GrantFiled: February 8, 2010Date of Patent: August 27, 2013Assignee: The Wistar InstituteInventor: Emmanuel Skordalakes
-
Publication number: 20130203854Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.
-
Publication number: 20130197093Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: ALLERGAN, INC.Inventor: ALLERGAN, INC.